LIVE

VTRS

Viatris Inc.

VTRS

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $18.8B

$16.63

▲ +2.75%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$8.63 - $17.53

P/E

-63.00

Fwd P/E

6.74

Beta

0.90

Div Yield

2.97%

Avg Vol

10.8M

Shares Out

1.2B

Mkt Cap

$18.8B

Price action

Price chart

Up 73.2% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Extensive Global Distribution Network
  • Diverse Pharmaceutical Portfolio
  • Cost-Effective Manufacturing Capabilities
  • Strong Regulatory Compliance Infrastructure
▼

Bear Case

1 risk

  • Average volatility.

Growth

Turning profitable

Expanding Biosimilars Market

Value

Deep value opportunity - significant discount to Large Cap Pharma peers

Momentum

Hot

+20.4% over 3m

Quality

Stable

Excellent business quality

Dividend

Solid

2.97% yield

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 6, 2026

“
Q2 26 RECAP

MAY 7, 2026

Reported EPS of $0.59 vs $0.52 consensus (+13.5% surprise). Revenue of $3.5B vs $3.4B expected (+4.8%). Beat on both top and bottom lines.

EPS beat +13.5%
Rev beat +4.8%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+13.5%

Next: May 6, 2026

Revenue trend · last 8Q

—

—

-8%

-11%

-6%

+0%

+5%

+8%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$3.8B

$3.8B

$3.5B

$3.3B

$3.6B

$3.8B

$3.7B

$3.5B

Margins · last 8Q

Gross

—

Operating

—

Profit

5.0%

View full earnings history →

Wall Street consensus

5 analysts · 60% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

3

60%

Hold

2

40%

Sell

0%

Median Price Target

$21.00

▲ +26.3% vs $16.63

Low $20.00
Median $21.00
High $22.00

Latest: Barclays · $22.00 · May 19, 2026

2 analysts covering

View full analyst page →

vs Industry

How VTRS stacks vs Drug Manufacturers - Specialty & Generic

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.